<DOC>
	<DOCNO>NCT00006362</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness PS-341 treating patient advance cancer .</brief_summary>
	<brief_title>PS-341 Treating Patients With Advanced Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose toxicity PS-341 patient advanced malignancy . - Determine , preliminary manner , therapeutic activity regimen patient . OUTLINE : This dose-escalation , multicenter study . - Regimen A : Patients receive PS-341 IV twice weekly 4 week . Treatment repeat every 6 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos PS-341 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 1 3-4 2 6 patient experience dose-limiting toxicity . - Regimen B : Once MTD determine regimen A , patient receive PS-341 IV twice weekly 2 week . Treatment repeat every 3 week absence disease progression unacceptable toxicity . Patients follow 3 month . PROJECTED ACCRUAL : A maximum 78 patient accrue study within 14 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Proteasome Inhibitors</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven advanced malignancy , include nonHodgkin 's lymphoma ( NHL ) , know standard therapy potentially curative definitely capable extend life expectancy Patients Bcell lymphoproliferative disorder leukemic phase eligible maximum tolerate dose establish NHL patient must meet following condition : No great 25 % bone marrow involve No symptomatic brain metastasis Prior brain metastasis allow definitively treat ( radiotherapy and/or surgery ) stable least 8 week PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST ALT great 2.5 time ULN ( 5 time ULN liver involvement ) Renal : Creatinine great 1.5 time ULN Cardiovascular : No New York Heart Association class III IV heart disease Other : No uncontrolled infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior biologic therapy immunotherapy No concurrent immunotherapy Chemotherapy : At least 4 week since prior chemotherapy ( 6 week mitomycin nitrosoureas ) recover No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics No prior radiotherapy great 30 % bone marrow At least 4 week since prior radiotherapy No concurrent radiotherapy Surgery : See Disease Characteristics Other : No concurrent antiretroviral therapy ( HAART ) HIV positive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>monoclonal gammopathy undetermined significance</keyword>
	<keyword>isolated plasmacytoma bone</keyword>
	<keyword>extramedullary plasmacytoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>untreated hairy cell leukemia</keyword>
	<keyword>progressive hairy cell leukemia , initial treatment</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>primary systemic amyloidosis</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>